TIDMTRX

Tissue Regenix Group PLC

11 October 2017

Hardman Research: Dual revenue stream growth

Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, bringing in synergistic bone regeneration technology. FY'17 results will be the first to reflect the acquisition and will include 5 months of the enlarged entity. The 1H'17 results presented here are for stand-alone TRX, and show organic growth, both from the EU jv and from DermaPure, to a GBP1.38m total.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/11.10.17-dual-revenue-stream-growth.pdf

 
 To contact us:          Contacts:       mh@hardmanandco.com 
  Hardman & Co            Dr Martin       dmh@hardmanandco.com 
  35 New Broad Street     Hall            gp@hardmanandco.com 
  London                  Dr Dorothea 
  EC2M 1NH                Hill 
  www.hardmanandco.com    Dr Gregoire 
  Follow us on Twitter    Pave 
  @HardmanandCo 
 
                          +44 20 7194 
                          7622

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFERIELILID

(END) Dow Jones Newswires

October 11, 2017 02:15 ET (06:15 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Tissue Regenix Charts.
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Tissue Regenix Charts.